Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | RAD52 | P43351 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | CHKA | P35790 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888470 | 0.93 | CHKA (0.60) | CHRNA7MAPTSMN1; SMN2GAARAD52 | |
| SCHEMBL11956080 | 0.84 | CYP2D6 (0.59) | CHRNA7SMN1; SMN2CHKA | |
| SCHEMBL28112415 | 0.82 | CHKA (0.80) | MAPTSMN1; SMN2GAAKDM4ECHKA | |
| SCHEMBL25698053 | 0.80 | CHKA (0.57) | CHKAADRB2NCF1PLD1HRH3 | |
| SCHEMBL4715235 | 0.80 | CHKA (0.57) | CHKAADRB2NCF1PLD1HRH3 | |
| SCHEMBL27584817 | 0.79 | CHKA (0.52) | MAPTCHKAADRB2NCF1PLD1 | |
| SCHEMBL17828013 | 0.79 | CHKA (0.52) | KDM4EGFERCHKAADRB2NCF1 | |
| SCHEMBL16546681 | 0.79 | CHKA (0.52) | CHRNA7CHKAADRB2NCF1PLD1 | |
| SCHEMBL1101883 | 0.79 | CHRNA7 (1.00) | CHRNA7MAPTSMN1; SMN2GAARAD52 | |
| SCHEMBL13168231 | 0.79 | CYP2C9 (0.54) | CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (GA) | 2022-05-17 | — | — | US | disclosed |
| WO-2022005898-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021203011-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021101919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021046437-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046447-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-0597411-B1 | Process for the preparation of phthalocyanine reactive dyes | BASF AG (DE) | 1999-04-28 | — | — | EP | disclosed |
| US-5516901-A | Preparation of reactive phthalocyanine dyes | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | disclosed |
| US-5444163-A | Preparation of reactive phthalocyanine dyes | BASF AKTIENGESELLSCHAFT (DE) | 1995-08-22 | — | — | US | disclosed |
| EP-0602562-A1 | Process for the preparation of phthalocyanine reactive dyes | BASF Aktiengesellschaft (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0597411-A1 | Process for the preparation of phthalocyanine reactive dyes | BASF Aktiengesellschaft (DE) | 1994-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | CHRNA7 4295/4885MAPT 2246/4885SMN1; SMN2 1682/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | CHRNA7 1047/4885MAPT 3303/4885SMN1; SMN2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.